Compare TKO & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TKO | RDY |
|---|---|---|
| Founded | 1980 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.5B | 11.6B |
| IPO Year | N/A | N/A |
| Metric | TKO | RDY |
|---|---|---|
| Price | $202.13 | $14.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 1 |
| Target Price | ★ $217.47 | $16.90 |
| AVG Volume (30 Days) | ★ 1.1M | 938.9K |
| Earning Date | 11-05-2025 | 01-22-2026 |
| Dividend Yield | ★ 1.50% | 0.50% |
| EPS Growth | N/A | ★ 9.95 |
| EPS | ★ 1.85 | 0.79 |
| Revenue | $2,545,175,000.00 | ★ $3,851,623,984.00 |
| Revenue This Year | $69.99 | $6.16 |
| Revenue Next Year | $29.75 | $2.57 |
| P/E Ratio | $109.02 | ★ $17.87 |
| Revenue Growth | N/A | ★ 14.10 |
| 52 Week Low | $133.07 | $12.26 |
| 52 Week High | $212.49 | $16.17 |
| Indicator | TKO | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 69.55 | 57.67 |
| Support Level | $176.00 | $13.64 |
| Resistance Level | $194.86 | $14.20 |
| Average True Range (ATR) | 5.11 | 0.16 |
| MACD | 2.15 | 0.05 |
| Stochastic Oscillator | 98.21 | 98.25 |
TKO Group Holdings Inc is a sports and sports entertainment company that operates combat sports and sports entertainment companies. It owns and manages valuable sports and entertainment intellectual property. The company distributes content and monetizes its intellectual property through four principal activities: Media Rights and Content, Live Events, Sponsorship, and Consumer Products Licensing. The company has two reportable segments, UFC and WWE. The company generates majority of revenue from the UFC segment. The UFC segment revenue consists of media rights fees associated with the distribution of its programming content, ticket sales, and site fees associated with the business's international live events, sponsorship, and consumer products licensing agreements of UFC-branded products.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.